Ground-breaking research that will affect common cancers
The broad spectrum utility of a Cyr61 suppressing therapeutic is tacitly implicated by the many types of cancers already known to over-express Cyr61, which include:
Far-reaching potential with a huge impact
In addition to the anticancer therapeutics possibilities, there are a number of other applications using the CCN technology platform that can be developed into very profitable revenue streams, including:
Detection kits for the presence of hCyr61
If MUNIN’s anti-angiogenesis anti-cancer therapeutics successfully passes clinical trials, doctors with cancer patients would require the use of detection kits for the presence of hCyr61 in order to prescribe MUNIN’s lead anti-cancer therapeutic. Detection kit sales should at a minimum equal to the number of new patients who use our lead product, with a maximum volume of sales being the number of new cases of solid state tumors known to over-express hCyr61.
hCyr61 as a supplement for growing stem cells
An additional aspect of our research could be focused on demonstrating that Cyr61 can support undifferentiated hematopoietic stem cell growth in vitro.
hCyr61 as a cartilage and bone growth enhancing agent
Another aspect of our R&D interest is predicated on demonstrating that Cyr61 and Nov can be used as wound healing agents and cartilage and bone growth stimulators.
Treatment of retinopathy in Type I diabetics
As many as 40,000 new cases of blindness occur each year in the U.S. among people with diabetes because of vision-threatening pathological angiogenesis (which occurs in 50 % of all type I diabetic patients, accounting for over 700,000 patients with progressive diabetic retinopathy). Treatment of type I diabetics for early stages of retinopathy would yield annual savings of $ 101-167 million.
hCyr61 as a wound-healing enhancing agent
hCyr61 could be used to potentially speed up the wound-healing process, helping in the treatment of chronic ulcers, healing of localized tissue damage (e.g. amputations), bone marrow transplantation and reconstitution therapies. The health-care markets for therapeutic local angiogenic-inducing agents are commercially significant. For example, between 60,000 and 120,000 lower limb amputations are performed yearly in the U.S. (due to damage leading to diseased tissue, as a result of, e.g. trauma, diabetes, or peripheral vascular disease); however, the 3-year survival rate after amputation is only 50 %. Furthermore, the annual care of pressure ulcers in the U.S. is estimated to cost over $ 1.3 billion.
Treatment for rheumatoid arthritis
Over 2 million people in the U.S. annually seek medical treatment for rheumatoid arthritis. One study revealed that in families with a juvenile rheumatoid arthritis patient 5% of mean family income was spent on health care for that patient.
hCyr61 as an angiogenesis inducing agent to stimulate local vessel regeneration to treat peripheral vascular and cardio-vascular problems
The pipeline of development projects based on CCN provides huge future growth potential beyond the already large magnitude of MUNIN’s anti-cancer application. Besides developing these projects on our own, it is also possible for MUNIN to collaborate with other commercial concerns that have the requisite interest and resources to develop these patent protected products.